NewAmsterdam Pharma (NAMS) Operating Margin (2023 - 2026)

NewAmsterdam Pharma has disclosed Operating Margin across 4 years of filings, most recently posting 1921.71% for Q1 2026.

• Operating Margin for Q1 2026 came in at 1921.71%, up 39276.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 953.59% (down 55111.0% YoY), and the FY2025 annual result was 1002.9%, down 61599.0% from the prior year.
• Operating Margin came in at 1921.71% for Q1 2026 at NewAmsterdam Pharma, up from 206187.5% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 85.89% in Q3 2024 to a low of 206187.5% in Q4 2025.
• The 4-year median for Operating Margin is 2306.93% (2024), against an average of 18779.11%.
• Across the five-year window, Operating Margin jumped 602193 bps in 2024 and slumped 20584903 bps in 2025, its largest moves.
• NewAmsterdam Pharma's Operating Margin stood at 6360.4% in 2023, then jumped by 95 bps to 338.47% in 2024, then sank by 60818 bps to 206187.5% in 2025, then surged by 99 bps to 1921.71% in 2026.
• The last three Operating Margin figures came in at 1921.71% (Q1 2026), 206187.5% (Q4 2025), and 15845.69% (Q3 2025), per Business Quant data.